BACKGROUND Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins.
P otent cholesteryl ester transfer protein (CETP) inhibitors substantially increase high-density lipoprotein cholesterol (HDL-C) levels as monotherapy and in combination with statins (1) (2) (3) (4) . Levels of HDL-C are known to inversely associate with the prevalence and incidence of atherosclerotic cardiovascular disease (ASCVD) in epidemiological studies, independently of all other major risk factors (5) . Randomized controlled trials with HDL-C-raising medications and genetic mechanisms that raise HDL-C levels have suggested that HDL-C may not be causally associated with ASCVD (6) (7) (8) (9) . However, Mendelian randomization studies have linked common CETP variants associated with low CETP activity, high HDL-C, and reduced LDL-C to a 4% lower risk of myocardial infarction (7) .
Cholesterol efflux from peripheral tissues is a key function of HDL particles, and the first step of reverse cholesterol transport to the liver for biliary secretion (10) . Recent studies have shown that cholesterol efflux capacity (CEC) is inversely associated with prevalent ASCVD (11, 12) and incident cardiovascular events in a population-based cohort without cardiovascular disease at baseline (11, 13) . These associations were independent of HDL-C and traditional cardiovascular risk factors, which suggested that the HDL-C level is only a modest biomarker of HDL function, and that CEC may be more closely correlated with cardiovascular outcomes.
Lipid-poor pre-beta-1 HDL particles are believed to be one of the primary acceptors of cholesterol effluxed from macrophages via the adenosine triphosphate-binding cassette transporter A1 (ABCA1) (14) . ABCA1 is primarily localized in the plasma membrane of cells, and ABCA1-mediated cholesterol efflux to lipid-poor pre-beta-1 particles is essential for HDL formation. Thus, ABCA1-specific cholesterol efflux is generally correlated with lipid-poor prebeta-1 HDL, but is not correlated with large HDL particles (15) . However, although ABCA1 is a major mediator of macrophage cholesterol efflux, HDL also promotes macrophage cholesterol efflux via ABCG1 and probably other pathways as well (16) . ABCG1 is also expressed in vascular endothelium, where it mediates cellular sterol efflux to large HDL particles (17) . Thus, ABCA1 and ABCG1 have complementary functions in mediating cholesterol efflux to HDL, and their association with cardiovascular disease is not clear (18) . However, data on the regeneration of prebeta-1 HDL and the role of ABCA1-specific cholesterol efflux following pharmacological CETP inhibition are limited.
In this study, we assessed the changes from baseline in CEC and HDL subclasses after 12 weeks of treatment with evacetrapib monotherapy, statin monotherapy, or evacetrapib in combination with statins in dyslipidemic patients. The relationship among changes in CEC and CETP mass or activity, HDL subclass, HDL-C, and apolipoprotein A-I (apoA-I) concentrations was also assessed. We demonstrate that evacetrapib, at different doses as monotherapy and at the 100 mg/day dose in combination with statins, increased pre-beta-1, alpha-1, and alpha-2 HDL levels, with corresponding increases in both non-ABCA1-and ABCA1-specific CEC. CEC (total, ABCA1-specific, and non-ABCA1-specific) was quantified in blood samples by depleting patient serum of apoB particles using polyethylene glycol precipitation (11) . The intra-assay and interassay coefficients of variation were 8% and 10% for total efflux, and 9% and 15% for ABCA1-specific efflux, respectively (11) . Non-ABCA1-specific efflux was calculated as the difference between total and ABCA1specific efflux. Pre-beta-1 HDL levels were measured in plasma using an immunofixation method validated by the isotope dilution technique by O'Connor et al. (19) . Assays were run in duplicate with intra-assay and interassay coefficients of variation of 6% and 7%, respectively (20) . HDL subclasses (alpha-and pre-alpha-1, -2, -3, and -4, and pre-beta-1) were also quantitatively determined by nondenaturing 2D Figure 2 and Online Tables 5 and 6. Evacetrapib monotherapy significantly increased alpha-1 by 208%, pre-alpha-1 by 174%, and pre-beta-1 HDL by 45% compared with placebo, and these increases were dose-dependent.
METHODS
Evacetrapib monotherapy also increased alpha-2 by 14% and decreased pre-alpha-3 by 24%, but these effects were not dose-dependent. Pooled statin monotherapy had no significant effect on HDL subpopulations, except for a 26% increase in prealpha-2 HDL levels compared with placebo. Pooled evacetrapib combined with statins also significantly increased alpha-1 by 164%, pre-alpha-1 by 106%, and pre-beta-2 by 40% compared with pooled statin monotherapy, and these increases were evident for all statins. As seen for evacetrapib monotherapy, an increase in alpha-2 and decrease in pre-alpha-3 were also observed with evacetrapib combined with statins versus statin monotherapy. Alpha-4 HDL levels were also significantly increased with evacetrapib combined with statins.
CORRELATION ANALYSES. Correlations between total, non-ABCA1-specific, or ABCA1-specific cholesterol efflux and lipid variables at baseline are shown in Table 1 . ApoA-I, HDL-C, alpha-1, and pre-beta-1 HDL levels were also significantly correlated with total cholesterol efflux after 12 weeks of treatment, and were found in both pooled treatment groups (evacetrapib monotherapy and evacetrapib plus statins) ( Table 2) . Changes in pre-beta-1 HDL were directly correlated with total, non-ABCA1-, and ABCA1-specific efflux in the evacetrapib plus statin group, but were not correlated with the evacetrapib monotherapy group.
DISCUSSION
This study represents the largest and most systematic evaluation of the effects of a CETP inhibitor on HDL CEC and on the related measure of pre-beta-1 HDL as assessed by 2 independent methods. We investigated the potent CETP inhibitor evacetrapib as monotherapy or in combination with 3 different statins on these HDL-related parameters, and found that evacetrapib, both as monotherapy and combined with statins, significantly increased total CEC, non-ABCA1specific CEC, ABCA1-specific CEC, and pre-beta-1 HDL (Central Illustration). These robust findings demonstrate that evacetrapib has effects on HDL function beyond its effect in raising plasma HDL-C levels.
The efflux of macrophage cholesterol to HDLrelated acceptors may be a mechanism that is atheroprotective (16) . ABCA1 transports cholesterol to lipid-poor apoA-I particles, which are often described These findings indicate that CETP activity, in a given individual, may influence CEC and generation of prebeta-1 HDL. These data support the findings from Mendelian randomization studies that linked common CETP variants associated with low CETP activity to lower cardiovascular risk (7) . Association of some variants and CETP activity with CEC and pre-beta-1 HDL concentrations have been described (26) .
STUDY LIMITATIONS. One potential limitation in the current assessment of CEC is that macrophages used in ex vivo assays are exposed to different conditions than patients' macrophages in vivo and are not preexposed to the study drug. However, the results obtained with statin monotherapy in this study suggest that the test macrophages behaved as expected, because decreased intracellular cholesterol and oxysterol concentrations induced by statins are known to lead to increased transcription of micro-RNA33 CETP inhibition has been well-established to increase plasma HDL-C levels, but its effect on HDL function, as assessed by CEC, has been uncertain.
Torcetrapib monotherapy resulted in increased total CEC at the 60 mg/day dose used in the cardiovascular outcomes study ILLUMINATE (Investigation of Lipid Level management to Understand its iMpact IN ATherosclerotic Events) (9) and at the 120 mg/day dose (28) in proportion to the magnitude of HDL-C increase with these 2 doses. The better cholesterol efflux with the higher dose of torcetrapib is consistent with the observation that subjects with greater HDL-C and apoA-I increases on torcetrapib showed more pronounced regression of coronary atherosclerosis and appeared to have better cardiovascular outcomes (29) .
Anacetrapib monotherapy, at a dose 3-fold higher than that being studied in the cardiovascular outcomes study REVEAL (Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification), also increased total CEC (30) . However, differences in assay methodology make it difficult to compare data, because the torcetrapib and anacetrapib studies used isolated HDL, whereas a supernatant of apoB-depleted serum was used in the present study. Finally, dalcetrapib 600 mg/day in combination with a statin also minimally increased total CEC (31), in proportion with a relatively small HDL-C increase, which was consistent with the no effects on cardiovascular outcomes in the dal-OUTCOMES (Effects of the Cholesterol Ester
Transfer Protein Inhibitor Dalcetrapib in Patients with
Recent Acute Coronary Syndrome) study (6) . In that study, Ray et al. (31) used the same methodology to evaluate CEC that was used in the present study, but they were not able to show any effect of dalcetrapib treatment on ABCA1-specific CEC. Thus, the modest increase in total CEC with torcetrapib, anacetrapib, and dalcetrapib was largely due to non-ABCA1-specific efflux, with ABCG1 playing a major role in mediating the efflux potential. No previous studies have rigorously assessed the impact of CETP inhibition on ABCA1-specific efflux or on pre-beta-1 HDL, which is the major acceptor of ABCA1-mediated efflux.
In this comprehensive study of evacetrapib, the most unique finding was a substantial, consistent increase in ABCA1-specific efflux, both in monotherapy and in combination with a statin. This was accompanied by significant increases in pre-beta-1 HDL levels as measured by 2 independent assays. The correlations between pre-beta-1 HDL concentrations and Abbreviations as in Table 1 . Because our study involved statin monotherapy arms for comparison with evacetrapib in combination with statins, we had the opportunity to perform the largest systematic analysis of the effects of different statins on CEC to date. Previous studies (27, 32) were small, were generally limited to 1 statin, and used methods to assess CEC that were less well-established.
The recent report by Niesor et al. (27) showed that statins increased micro-R33 expression and decreased ABCA1 expression and cholesterol efflux from peripheral tissues; there was a differential effect of relatively hydrophobic statins compared with more hydrophilic statins on the degree of cholesterol efflux reduction. The present study adds incremental information with regard to the effect of different statins on ABCA1 cholesterol efflux, because both rosuvastatin and simvastatin significantly reduced total CEC, non-ABCA1-specific efflux, and ABCA1-specific efflux, whereas atorvastatin had no significant effect on CEC. This is interesting in light of the previous observations that atorvastatin had less effect in raising HDL-C levels compared with rosuvastatin and simvastatin (33) . The mechanisms by which statins reduce CEC are not understood. Even more interesting, the effect of evacetrapib, when given in combination with a statin, on CEC and pre-beta-1 HDL appears to be slightly reduced with respect to evacetrapib monotherapy, although the correlation between changes in total and ABCA1-specific CEC and pre-beta-1 HDL levels remained robust. The mechanisms underlying the effects of potent CETP inhibition combined with statin therapy on CEC and pre-beta-1 HDL will need to be elucidated in future studies.
CONCLUSIONS
Potent CETP inhibition with evacetrapib unexpectedly increased not only total CEC but also ABCA1-specific CEC and pre-beta-1 HDL in a dose-dependent fashion. Furthermore, this effect was slightly reduced by co-administration with statins, which proved to decrease CEC as monotherapy. These results reveal the complex effects of potent CETP inhibition on HDL remodeling and function that require more investigation. They also raise the possibility, in light of recent prospective data that inversely linked CEC to incident cardiovascular events, that this increase in CEC might have the potential to reduce cardiovascular risk. week course of treatment with evacetrapib, either alone or in combination with statin therapy, increases ABCA1-specific cholesterol efflux and pre-beta-1 HDL levels.
TRANSLATIONAL OUTLOOK: Further study is needed to determine whether the increase in CEC brought about by treatment with evacetrapib can reduce cardiovascular risk. Evacetrapib Increases Cholesterol Efflux
